Lopresti Brian J, Royse Sarah K, Mathis Chester A, Tollefson Savannah A, Narendran Rajesh
Departments of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Departments of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
J Neurochem. 2023 Feb;164(3):364-400. doi: 10.1111/jnc.15615. Epub 2022 May 10.
With the emergence of positron emission tomography (PET) in the late 1970s, psychiatry had access to a tool capable of non-invasive assessment of human brain function. Early applications in psychiatry focused on identifying characteristic brain blood flow and metabolic derangements using radiotracers such as [ O]H O and [ F]FDG. Despite the success of these techniques, it became apparent that more specific probes were needed to understand the neurochemical bases of psychiatric disorders. The first neurochemical PET imaging probes targeted sites of action of neuroleptic (dopamine D receptors) and psychoactive (serotonin receptors) drugs. Based on the centrality of monoamine dysfunction in psychiatric disorders and the measured success of monoamine-enhancing drugs in treating them, the next 30 years witnessed the development of an armamentarium of PET radiopharmaceuticals and imaging methodologies for studying monoamines. Continued development of monoamine-enhancing drugs over this time however was less successful, realizing only modest gains in efficacy and tolerability. As patent protection for many widely prescribed and profitable psychiatric drugs lapsed, drug development pipelines shifted away from monoamines in search of novel targets with the promises of improved efficacy, or abandoned altogether. Over this period, PET radiopharmaceutical development activities closely paralleled drug development priorities resulting in the development of new PET imaging agents for non-monoamine targets. Part one of this review will briefly survey novel PET imaging targets with relevance to the field of psychiatry, which include the metabotropic glutamate receptor type 5 (mGluR5), purinergic P X receptor, type 1 cannabinoid receptor (CB ), phosphodiesterase 10A (PDE10A), and describe radiotracers developed for these and other targets that have matured to human subject investigations. Current limitations of the targets and techniques will also be discussed.
随着20世纪70年代末正电子发射断层扫描(PET)的出现,精神病学领域有了一种能够对人类大脑功能进行非侵入性评估的工具。精神病学的早期应用主要集中在使用诸如[O]H₂O和[F]FDG等放射性示踪剂来识别大脑血流和代谢紊乱的特征。尽管这些技术取得了成功,但显然需要更具特异性的探针来理解精神疾病的神经化学基础。首批神经化学PET成像探针靶向抗精神病药物(多巴胺D受体)和精神活性药物(5-羟色胺受体)的作用位点。基于单胺功能障碍在精神疾病中的核心地位以及单胺增强药物在治疗这些疾病方面取得的显著成效,在接下来的30年里,用于研究单胺的PET放射性药物和成像方法不断涌现。然而,在此期间单胺增强药物的持续研发成效较小,在疗效和耐受性方面仅取得了适度进展。随着许多广泛使用且利润丰厚的精神科药物专利保护到期,药物研发方向从单胺转向寻找有望提高疗效的新靶点,甚至完全放弃了单胺相关研究。在此期间,PET放射性药物的研发活动与药物研发重点紧密平行,导致了针对非单胺靶点的新型PET成像剂的开发。本综述的第一部分将简要概述与精神病学领域相关的新型PET成像靶点,其中包括代谢型谷氨酸受体5(mGluR5)、嘌呤能P2X受体1型、大麻素受体1型(CB1)、磷酸二酯酶10A(PDE10A),并描述针对这些靶点以及其他已成熟到人体研究阶段的靶点所开发的放射性示踪剂。还将讨论这些靶点和技术目前存在的局限性。